Kineta Current Ratio 2014-2024 | KANT
Kineta current ratio from 2014 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Kineta Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-06-30 |
$0.00B |
$0.01B |
0.14 |
| 2024-03-31 |
$0.00B |
$0.01B |
0.25 |
| 2023-12-31 |
$0.01B |
$0.01B |
0.85 |
| 2023-09-30 |
$0.01B |
$0.01B |
1.03 |
| 2023-06-30 |
$0.01B |
$0.01B |
1.39 |
| 2023-03-31 |
$0.01B |
$0.01B |
0.80 |
| 2022-12-31 |
$0.01B |
$0.01B |
1.18 |
| 2022-09-30 |
$0.01B |
$0.00B |
2.21 |
| 2022-06-30 |
$0.02B |
$0.01B |
1.93 |
| 2022-03-31 |
$0.02B |
$0.01B |
1.90 |
| 2021-12-31 |
$0.01B |
$0.01B |
0.78 |
| 2021-09-30 |
$0.05B |
$0.02B |
2.70 |
| 2021-06-30 |
$0.06B |
$0.02B |
3.26 |
| 2021-03-31 |
$0.07B |
$0.02B |
3.61 |
| 2020-12-31 |
$0.09B |
$0.03B |
2.84 |
| 2020-09-30 |
$0.04B |
$0.01B |
6.76 |
| 2020-06-30 |
$0.05B |
$0.01B |
6.69 |
| 2020-03-31 |
$0.06B |
$0.01B |
7.26 |
| 2019-12-31 |
$0.02B |
$0.01B |
3.26 |
| 2019-09-30 |
$0.08B |
$0.01B |
6.89 |
| 2019-06-30 |
$0.09B |
$0.01B |
8.19 |
| 2019-03-31 |
$0.11B |
$0.01B |
11.30 |
| 2018-12-31 |
$0.12B |
$0.01B |
14.05 |
| 2018-09-30 |
$0.05B |
$0.01B |
4.17 |
| 2018-06-30 |
$0.06B |
$0.01B |
6.70 |
| 2018-03-31 |
$0.07B |
$0.01B |
8.09 |
| 2017-12-31 |
$0.08B |
$0.01B |
7.70 |
| 2017-09-30 |
$0.05B |
$0.01B |
4.21 |
| 2017-06-30 |
$0.06B |
$0.01B |
5.65 |
| 2017-03-31 |
$0.08B |
$0.01B |
9.23 |
| 2016-12-31 |
$0.09B |
$0.01B |
10.31 |
| 2016-09-30 |
$0.10B |
$0.01B |
8.68 |
| 2016-06-30 |
$0.04B |
$0.01B |
3.88 |
| 2016-03-31 |
$0.05B |
$0.01B |
5.91 |
| 2015-12-31 |
$0.02B |
$0.01B |
1.52 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.01B |
$0.01B |
1.76 |
| 2013-12-31 |
$0.01B |
$0.00B |
1.98 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
